BEI-inactivated PRRSV candidate vaccine was developed using local Kazakh viral strains.
Immune response and clinical disease were compared with a commercial PRRSV vaccine.
Compared to commercial vaccine our vaccine induced better cross-protective response.
Use of a potent adjuvant and local PRRSV strains in the vaccine formulation is beneficial.